Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Sep 1;47(9):e65-e66.
doi: 10.2337/dc24-0730.

Use of a Dual GIP/GLP-1 Receptor Agonist in HNF1A-MODY and HNF4A-MODY

David T Broome  1 , Alina Mehdi  1 , Colby Chase  2 , Maria Foss de Freitas  1 , Brigid E Gregg  1 , Elif A Oral  1 , William H Herman  1
Affiliations
Case Reports

Use of a Dual GIP/GLP-1 Receptor Agonist in HNF1A-MODY and HNF4A-MODY

David T Broome et al. Diabetes Care. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Duality of Interest. D.T.B. is a research investigator for Fractyl Health Laboratories and Rhythm Pharmaceuticals. M.F.d.F. is an advisory board member for PTC Pharmaceuticals and was a scientific presenter in a symposium funded by Amryt Pharmaceuticals. E.A.O. has received grant support from Aegerion Pharmaceuticals (manufacturer of metreleptin), Akcea Therapeutics, Ionis Pharmaceuticals, Gemphire Therapeutics, Novo Nordisk, Rhythm Pharmaceuticals, Fractyl Health Laboratories, and GI Dynamics. E.A.O. has served as an advisor and/or a consultant to Aegerion Pharmaceuticals, Akcea Therapeutics, Ionis Pharmaceuticals, and Regeneron. E.A.O. has royalty rights from the use of metreleptin in lipodystrophy. W.H.H. is on data safety and monitoring boards for Merck Sharp & Dohme and Rivus Pharmaceuticals. No other potential conflicts of interest relevant to this article were reported.

References

    1. Pihoker C, Gilliam LK, Ellard S, et al. .; SEARCH for Diabetes in Youth Study Group . Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth. J Clin Endocrinol Metab 2013;98:4055–4062 - PMC - PubMed
    1. Shields BM, Hicks S, Shepherd MH, et al. . Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetalogia 2010;53:2504–2508 - PubMed
    1. Østoft SH, Bagger JI, Hansen T, et al. . Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial. Diabetes Care 2014;37:1797–1805 - PubMed
    1. Christensen AS, Hædersdal S, Storgaard H, et al. . GIP and GLP-1 potentiate sulfonylurea-induced insulin secretion in hepatocyte nuclear factor 1α mutation carriers. Diabetes 2020;69:1989–2002 - PMC - PubMed
    1. Garvey WT, Frias JP, Jastreboff AM, et al. .; SURMOUNT-2 Investigators . Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402:613–626 - PubMed

MeSH terms

Substances

LinkOut - more resources